Among all cancer types, RB1 alterations are more commonly identified in treatment‐refractory tumors with neuroendocrine or small‐cell features (e.g., small‐cell lung cancer), which may arise in multiple organs and indicate a poor prognosis [3, 5]. The gene discussed is RB1; the disease is cancer.